报价延迟最少15分钟:2026/01/09 11:17 EST
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
3.225 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-8.07/-5.53
|
|
企业价值
14.44M
|
| 资产负债 |
|
每股账面净值
1.76
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer. |
